Rebound Therapy on Ventilatory Functions in Down Syndrome

Effect of Rebound Therapy on Ventilatory Functions in Children With Down Syndrome. A Randomized Controlled Trial

The purpose of this study is to examine the effects of rebound therapy on ventilatory functions in children with Down Syndrome.

Study Overview

• Status: Not yet recruiting
• Conditions: Down Syndrome
• Intervention / Treatment: Other: Chest Physical Therapy Protocol; Other: Rebound Therapy Protocol

Detailed Description

Down syndrome (DS) is one of the common congenital anomalies associated with a high rate of various medical disorders including congenital cardiac defects, visual and auditory affection, musculoskeletal system, and autoimmune disorders. Respiratory involvement is common in DS and is a leading cause of death. Rebound therapy from quality of mini trampoline provides all benefits of other aerobic exercise without the stress impact usually associated with vigrous activity. Several studies support the use of rebound therapy among different areas while, there is no research conducted on ventilatory functions in children with Down Syndrome. Hence, there is need to study the effect of rebount therapy on ventilatory functions in children with Down Syndrome.

Fourty children with Down syndrome (based on power analysis) from both sexes (9-13 years) will be recruited from different schools of special education. They will be divided randomly into control group (20 children) and study group (20 children). The control group will receive a chest physical therapy protocol that included respiratory exercises and incentive spirometer training. The study group will receive a rebound therapy using mini trampoline.

• Study Type: Interventional
• Enrollment (Estimated): 40
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Eman Wagdy, PH.D; Phone Number: 01008079576; Email: Eman.wagdy@pt.bsu.edu.eg

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Children ages will be ranged from 9 to 13 years old.
• Mild and moderate mental retardation with IQ level between 50-70 based on Stanford-Binet intelligence scale.
• Functional hearing and vision.
• Independent standing and walking.

Exclusion Criteria:

• Symptomatic pain.
• Musculoskeletal problems or/ atlanto-axial instability.
• Rheumatic and congenital heart disease
• History of previous surgical operation
• Regular participation in any sport activities.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Chest Physical Therapy Protocol; Children with Down Syndrome will receive a chest physical therapy exercises	Other: Chest Physical Therapy Protocol; The chest physical therapy protocol include respiratory exercises and incentive spirometer training.
Experimental: Rebound Therapy Protocol; Children with Down Syndrome will receive a chest physical therapy exercises in addition to rebound therapy using mini trampoline.	Other: Chest Physical Therapy Protocol; The chest physical therapy protocol include respiratory exercises and incentive spirometer training.; Other: Rebound Therapy Protocol; The chest physical therapy protocol include respiratory exercises and incentive spirometer training + rebound therapy protocol using mini-trampoline training

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Forced Vital Capacity (FVC)	Spirometry will be used to measure forced vital capacity (FVC). It is the maximum volume of gas that can be expired when the child exhales as forcefully and as rapidly as possible after a maximal inspiration to assess the overall ability to move air in and out of the lungs. It is expressed in liter/minute.	Up to 12 weeks
Forced Expiratory Volume in the First Second (FEV1)	Spirometry will be used to measure forced expiratory volume in the first second (FEV1). It is the volume of gas expired over a given time interval (the first second) from the beginning of the FVC maneuver that reflects airflow in the large airways. It is expressed in liter/minute.	Up to 12 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Functional Mobility	Six-minute walk test will be used for measuring functional mobility. It is a sub-maximal test of aerobic capacity, in which the subjects walk as far as possible in 6 minutes (min.) around a premeasured distance	Up to 12 weeks
Chest Expansion	Tape measures will be used to measure chest expansion.	Up to 12 weeks

Collaborators and Investigators

• Sponsor: Beni-Suef University

Study record dates

Study Major Dates

• Study Start (Estimated): February 22, 2026
• Primary Completion (Estimated): May 22, 2026
• Study Completion (Estimated): May 22, 2026

Study Registration Dates

• First Submitted: February 15, 2026
• First Submitted That Met QC Criteria: February 15, 2026
• First Posted (Actual): February 20, 2026

Study Record Updates

• Last Update Posted (Actual): February 20, 2026
• Last Update Submitted That Met QC Criteria: February 15, 2026
• Last Verified: February 1, 2026

More Information

Terms related to this study

• Keywords: Down Syndrome; Spirometry; Mini-Trampoline
• Additional Relevant MeSH Terms: Neurologic Manifestations; Nervous System Diseases; Genetic Diseases, Inborn; Neurobehavioral Manifestations; Congenital Abnormalities; Abnormalities, Multiple; Intellectual Disability; Chromosome Disorders; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Down Syndrome
• Other Study ID Numbers: P.T.REC/012/006209

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No